All posts in " Novartis "

Novartis and Roche threaten to quit UK

By VT / April 13, 2010

. . . . Rob Evans and Sarah Boseley 04/11/2010 The pharmaceutical firms Novartis and Roche have threatened to pull out of Britain and relocate thousands of jobs abroad, in an ongoing row over pricing for the NHS and rules surrounding safety trials. The Swiss drug companies made their threats known in personal meetings […]

Novartis chief warns states over cancelled vaccine orders

By VT / January 28, 2010

Source: AFP BASEL, Switzerland — The head of Swiss pharmaceutical giant Novartis on Tuesday warned that governments now trying to cancel swine flu vaccine contracts might not be dealt with so swiftly in the next pandemic. Chairman and chief executive Daniel Vasella said those that had been reliable partners would be favoured. “The same governments […]

Novartis denies problems with swine flu vaccine

By VT / October 27, 2009

Swiss pharmaceutical group Novartis on Monday denied that it faced hurdles in gaining regulatory approval in Switzerland for one of its swine flu vaccines because of possible bacterial contamination.

Flu Vaccines and the Risk of Cancer

By VT / September 15, 2009

The new manufacturing process for flu shots, called cell-line technologies, are little understood and have the potential for serious, long term consequences.

The Engineering of Pandemics

By VT / September 10, 2009

Medical Mafia’s propaganda blitz was successful, and over a million previously healthy and happy American citizens were hypnotized and terrorized into placing the vaccine toxins into their bloodstreams.

Novartis hails single-dose H1N1 vaccine success

By VT / September 3, 2009

Racing to produce a huge quantity of vaccine to fight an expected tsunami of swine flu cases this fall, Novartis says that a single low dose of its Celtura jab produced an immune response sufficient to protect the volunteers enrolled in a small trial.

Vaccines- The Pharma’s Cauldron

By VT / August 6, 2009

Ingredients used in the vaccine are derived from the kidneys of African Green Monkeys who are first infected with a virus — U.S. patent No. 5911998 — Method of producing a virus vaccine from an African green monkey kidney cell line.